1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
2.
Battistini B, Chailler P, D’Orléans-Juste P, et al. Growth regulatory properties of endothelins. Peptides 1993; 14: 385-99.
3.
Kohan DE, Barton M. Endothelins in normal and abnormal kidney function. Am J Kidney Dis 2014; 63: 263-72.
4.
Dashwood MR, Tsui JC. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis 2002; 160: 297-304.
5.
Zhou Z, Wang J, Cao R, et al. Control of renal myofibroblast differentiation via endothelin-1 and the ETA receptor. Kidney Int 2018; 93: 143-57.
6.
Haribabu B, Verghese MW, Steeber DA, et al. Targeted disruption of the leukotriene B4 receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med 2000; 192: 433-8.
7.
Camilleri M. Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment Pharmacol Ther 2010; 32: 313-21.
8.
Hodges LM, Markova SM, Chinnathambi S, et al. Very early-onset inflammatory bowel disease associates with increased localisation of Ets transcription factor to the nucleus. Gut 2019; 68: 44-53.
9.
Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117: 636-47.
10.
Kohan DE, Feng Y. Endothelins in health and disease: a focus on the kidney. Clin Sci 2019; 133: 895-919.
11.
Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev 2016; 68: 357-418.
12.
Levin ER. Endothelins. N Engl J Med 1995; 333: 356-63.
13.
Takahashi H, Shibuya M, Ishiko T, et al. Increased plasma endothelin-1 level in patients with inflammatory bowel disease. Am J Gastroenterol 1992; 87: 1659-62.
14.
Mashimo H, He XD, Huang PL, et al. Neuronal constitutive nitric oxide synthase is involved in murine enteric inhibitory neurotransmission. J Clin Invest 1996; 98: 8-13.
15.
Takahashi T, Owyang C. Regional differences in the nitrergic innervation between the proximal and the distal colon in rats. Gastroenterology 1998; 114: 941-52.
16.
Hicks GA, Coldwell JR, Schafer K, et al. The P2X3 purinergic receptor agonist, ,-meATP, attenuates intestinal inflammation in DSS-induced colitis in mice through induction of apoptosis of activated immune cells. Purinergic Signal 2018; 14: 489-500.
17.
Takahashi T, Owyang C. Characterization of vagal pathways mediating gastric accommodation reflex in rats. J Physiol 1998; 506: 879-88.
18.
Dashwood MR, Tsui JC. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis 2002; 160: 297-304.
19.
Benyon RC, Iredale JP, Goddard S, et al. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996; 110: 821-31.
20.
Hong F, Chou H, Fiel MI, Friedman SL. Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory mechanisms, dosing, and window of efficacy. Dig Dis Sci 2009; 54: 257-64.
21.
Singh A, Mohanty I, Singh J, Rattan S. BDNF augments rat internal anal sphincter smooth muscle tone via RhoA/ ROCK signaling and nonadrenergic noncholinergic relaxation via increased NO release. Am J Physiol - Gastrointest Liver Physiol 2020; 318: G23-33.
22.
Singh A, Singh J, Rattan S. Evidence for the presence and release of BDNF in the neuronal and non-neuronal structures of the internal anal sphincter. Neurogastroenterol Motil 2022; 34: e14099.
23.
Singh A, Rattan S. BDNF rescues aging-associated internal anal sphincter dysfunction. Am J Physiol Gastrointest Liver Physiol 2021; 321: G87-97.
24.
Maekawa T, Balachandran R, Xie W, et al. Targeting endothelin receptor signalling overcomes fibrosis in scleroderma. Nat Commun 2020; 11: 3532.
25.
Fang B, Zhao Y, Li Z, Wang H. MiR-125a alleviates intestinal inflammation through down-regulation of endothelin receptor A expression in mice with inflammatory bowel disease. Biochem Biophys Res Commun 2022; 583: 1-6.
26.
Jerzak K, Ratnasekera C, Tang CL, Cheng LK. The role of the endothelin system in diabetic gastroparesis: a systematic review. Biomedicines 2021; 9 :1017.
27.
Yepuri G, Holdcroft A, Walmsley D, et al. A selective endothelin-A receptor antagonist reduces referred abdominal pain in patients with irritable bowel syndrome with diarrhea. Gastroenterology 2022 May 5: S0016-5085(22)00498-9.
28.
Yang Y, Wang H, Wu W, Sun D. Effects and mechanisms of endothelin receptor antagonists in adjuvant-induced arthritis. Int Immunopharmacol 2020; 89: 107085.
29.
Li P, Trinh K, Bian ZX. Deciphering signaling pathways involved in 5-HT-modulated colonic motility and secretion. Int J Mol Sci 2020; 21: 5709.
30.
Thompson K, Moeser AJ, Blikslager AT. Cannabinoids inhibit the enhanced propulsion induced by experimental dextran sulfate sodium (DSS)-colitis in mice. Front Vet Sci 2022; 9: 809117.
31.
Can G, Temel MA, Bayraktar E, et al. Investigation of the protective effects of cannabidiol on trinitrobenzene sulfonic acid-induced ulcerative colitis rat model. Inflammopharmacology 2020; 28: 737-48.
32.
Lake JI, Heuckeroth RO. Enteric nervous system development: migration, differentiation, and disease. Am J Physiol Gastrointest Liver Physiol 2013; 305: G1-24.
33.
Gershon MD. Developmental determinants of the independence and complexity of the enteric nervous system. Trends Neurosci 2010; 33: 446-56.
34.
Murch SH, Braegger CP, Sessa WC, MacDonald TT. High endothelin-1 immunoreactivity in Crohn’s disease and ulcerative colitis. Lancet 1992; 339: 381-5.
35.
Harrison M, Zinovkin D, Pranjol MZI. Endothelin-1 and its role in cancer and potential therapeutic opportunities. Biomedicines 2024; 12: 511.
36.
Bagnato A, Loizidou M, Pflug BR, et al. Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 2011; 163: 220-33.
37.
Filipovich T, Fleisher-Berkovich S. Regulation of glial inflammatory mediators synthesis: possible role of endothelins. Peptides 2008; 29: 2250-6.
38.
Filipovich-Rimon T, Fleisher-Berkovich S. Glial response to lipopolysaccharide: possible role of endothelins. Peptides 2010; 31: 2269-75.
39.
Horinouchi T, Terada K, Higashi T, Miwa S. Endothelin receptor signaling: new insight into its regulatory mechanisms. J Pharmacol Sci 2013; 123: 85-101.
40.
Pazhani J, Jayaraman S, Veeraraghavan VP, Jasmine S. Endothelin-1 axis as a therapeutic target in oral squamous cell carcinoma: molecular insights. J Stomatol Oral Maxillofac Surg 2024; 125: 101792.
41.
Singh H, Patel V. Role of molecular targeted therapeutic drugs in treatment of oral squamous cell carcinoma: development and current strategies-a review article. Glob Med Genet 2022; 9: 242-6.
42.
Kanai SM, Clouthier DE. Endothelin signaling in development. Development 2023; 150: dev201786.
43.
Schiffrin EL, Pollock DM. Endothelin system in hypertension and chronic kidney disease. Hypertension 2024; 81: 691-701.
44.
Błaszkiewicz M, Walulik A, Florek K, et al. Advances and perspectives in relation to the molecular basis of diabetic retinopathy-a review. Biomedicines 2023; 11: 2951.
45.
Banecki KMRM, Dora KA. Endothelin-1 in health and disease. Int J Mol Sci 2023; 24: 11295.
46.
Podyacheva E, Danilchuk M, Toropova Y. Molecular mechanisms of endothelial remodeling under doxorubicin treatment. Biomed Pharmacother 2023; 162: 114576.
